

May 26, 2025

To Shareholders,

Company Name: Renascience Inc.
Representative: Keisuke Furuta, President & CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

Notice of Change of Representative Director and Directors

The Company hereby announces that the Board of Directors has resolved at a meeting on May 26, 2025, to make changes in the Representative Director and other Directors. The change in the Directors will be officially decided after approval at the Company's 26th Annual General Meeting of Shareholders scheduled on June 26, 2025, and a subsequent meeting of the Board of Directors.

1. Changes of the Representative Director

(1) Reason for the change

The reason is due to change in the management structure following expiration of the term. The Company intends to expand into new areas, such as longevity/anti-aging, and to strengthen our pipeline development and commercialization activities.

(2) Details of the change

Name	New Position Name	Current job title
Keisuke Furuta	—	President & CEO
Toshio Miyata	Chairman and CEO	Chairman of the Board

(3) Date of the birth, brief personal history and number of shares held by the candidate for new representative director candidates

Name (Date of birth)	Brief personal record		Number of shares
Toshio Miyata (February 8, 1961)	April 1990	Special Research Fellow, Japan Society for the Promotion of Science	2,736,700
	June 1991	Research Assistant, Immunodeficiency Disease Research Division, Bioanalysis of Intractable Diseases, Research Institute for Microbial Diseases, The University of Osaka	
	May 1994	Lecturer, Department of Internal Medicine, Nagoya University Hospital	
	March 1997	Lecturer, Department of Molecular Pathology, Tokai University Institute of Medical Sciences, Department of Internal Medicine	
	April 1999	Associate Professor, Tokai University Institute of Medical	

	April 2003	Science and Department of Internal Medicine	
	April 2005	Professor, Tokai University Institute of Medical Science	
		Professor of Nephrology and Diabetes Mellitus, Tokai University School of Medicine	
	April 2006	Deputy Director, Tokai University Institute of Medical Sciences	
		Professor of Nephrology and Diabetes Mellitus, Tokai University School of Medicine	
	December 2007	Director, Tokai University Institute of Medical Science	
		Professor, Department of Molecular Pathology and Therapeutics, Tohoku University Graduate School of Medicine (current position)	
	April 2008	Special Advisor to Dean, Graduate School of Medicine, Tohoku University	
	January 2010	Director, Center for Advanced Medical Research and Translational Medicine (ART), Graduate School of Medicine, Tohoku University	
	October 2017	Associated Executive Vice President, Tohoku University (Industry-academia collaboration)	
	April 2018	Outside Director of the Company	
	April 2019	Associated Executive Vice Director (Interdisciplinary Research), Tohoku University	
	April 2020	Chairman of the Board of Directors of the Company (current position)	
	April 2023	Special Advisor to Dean, Graduate School of Medicine, Tohoku University (current position)	
	April 2024	Associated Executive Vice Director (Co-Creation research) (current position)	

(4) Scheduled date of inauguration

June 26, 2025

2. Changes in the Directors

(1) Date of the birth, brief personal history and number of shares held by the candidate for Director

Name	New Title	Current Title	Classification
Toshio Miyata	Chairman and CEO	Chairman, Director	Reappointment
Mitsuaki Kamata	Executive Vice President	—	New

(2) Date of the birth, brief personal history and number of shares held by the candidate for the new Representative Director

Name (Date of birth)	Brief personal record		Number of shares
Mitsuaki Kamata (November 30, 1962)	April 1986s	Joined the Ministry of Health, Labor and Welfare	—
	July 1993	Assistant Director of the Economic Affairs Division, Pharmaceutical Affairs Bureau, Ministry of Health, Labor and Welfare	
	May 1994	JETRO New York Center Pharmaceutical Affairs Department Director	
	August 1999	Liaison Officer for the Diet, General Affairs Division, Ministry of Health, Labour and Welfare	
	August 2005	Ministry of Health, Labor and Welfare, Nursing Affairs Bureau, Nursing Division, Nurse Recruitment Officer	
	August 2007	Director, Public Relations Office, General Affairs Division, Ministry of Health, Labour and Welfare	
	July 2009	Cabinet Secretariat Cabinet Counsellor (Cabinet Counsellor's Office, Prime Minister's Official Residence)	
	July 2011	Director, Economic Affairs Division, Medical Affairs Bureau, Ministry of Health, Labour and Welfare	
	July 2013	Director, General Affairs Division, Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare	
	October 2015	Chief Coordinator, Pharmaceuticals and Medical Devices Agency	
	June 2016	Director-General of the Bureau of International Medical Cooperation, National Center for Global Health and Medicine	
	July 2017	Cabinet Secretariat Cabinet Counselor (Deputy Director-	

	<p>July 2018</p> <p>March 2020</p> <p>November 2022</p>	<p>General of the Health and Medical Strategy Office)</p> <p>Director of the Tohoku Regional Health and Welfare Bureau</p> <p>Director-General of the Pharmaceutical and Food Safety Bureau of the Ministry of Health, Labour and Welfare</p> <p>Specially Appointed Professor at Tohoku University (current position)</p>	
--	---	--	--

(2) Candidates for Directors who are Audit and Supervisory Committee Members

Name	New Title	Current Title	Classification
Akihiko Ito	Outside Director Audit and Supervisory Committee Member	—	New
Satoshi Kitaura	Outside Director Audit and Supervisory Committee Member	—	New

(3) Retiring Directors

Name	Current Title
Keisuke Furuta	President & CEO
Yasunori Nishiyama	Outside Director Audit and Supervisory Committee Member

End